Phone
Email
ClinicalTrials.gov URL
NCT Name
NCT04705454
Acknowledgement
3 business days
ADC Therapeutics S.A.
EA Therapies for Single Patient
A U.S. EAP for loncastuximab tesirine (ADCT-402) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL).
EA Policies for Single Patient
If you cannot be treated by currently available drugs, cell therapy, or clinical trials, contact your treating physician to determine if the loncastuximab tesirine EAP is an option.